Ark Secures Reimbursement For Neuropad(R) From UK NHS Business Services Authority, UK
Oct 3rd 2008Drug InformationDiabetes
Ark Therapeutics Group plc (”Ark” or the “Company”) today announces that it has successfully achieved reimbursement from the UK NHS Business Services Authority for Neuropad®, an innovative diagnostic test to detect early stage peripheral autonomic neuropathy in the feet of diabetic patients. Neuropad® is the first product in a new diagnostic class to be available to the NHS on prescription.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
